VANCOUVER, BC and MESA, AZ, June 19, 2013 /PRNewswire/ - Avidus Management Group Inc. ("Avidus" or the "Company") (TSX-V: AVD, OTC: ASNHF) and its wholly owned subsidiary, Asantae, today announced that it held strategic meetings for its key distributors at an exclusive resort in Scottsdale, Arizona during the weekend of June 9 th.
At the meeting, a standardized plan for leadership, events, recognition, awards, and training systems was introduced. Avidus' new President, Doug Ridley said, "The key to growth and sustainability in network-marketing revolves around a standardized system and model for sales, recruiting, and distributor development. I was excited to introduce these programs to those in attendance."
Mr. Ridley also revealed F.A.S.T., an Avidus developed training system for network marketers. He commented, "F.A.S.T. is the backbone upon which we will create and introduce our distributor tools. It is a disciplined and duplicable system for building and sustaining long-term growth in network-marketing."
In addition, insight was given to the near-term product roadmap. Dan Lundell, Avidus CEO, explained, "Our product development program strictly adheres to our core mission to address chronic low-grade inflammation, which is among the leading causes of modern disease. I look forward to revealing more information about our newest product next month."Additional information about the new product launch will be announced in July. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. About Avidus Avidus Management Group Inc. ( www.asantae.com) (TSX-V: AVD, OTC: ASNHF) through its wholly owned subsidiary, Asantae, is a producer and marketer of innovative nutritional products through direct and network marketing channels. The ingredients in Avidus' products have been shown to reduce chronic low-grade inflammation and oxidative stresses which, according to scientific and medical research, are the underlying conditions for most modern epidemic diseases (diabetes, heart disease, obesity, stroke, etc.). This news release may contain forward-looking statements relating to the Company's operations or to the environment in which it operates. Such statements are based on operations, estimates, forecasts and projections. They are not guarantees of future performance and involve risks and uncertainties that are difficult to predict and may be beyond the Company's control. A number of important factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements, including those set forth in the Company's regulatory filings. In addition, such statements relate to the date on which they are made and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, save and except as may be required by applicable securities laws.